Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stockwatch: Don't Fear The Pricing Reaper

Executive Summary

The drug pricing debate has tarred many brushes in the pharmaceutical value chain. Whilst politicians may not yet be able to distinguish between the brazen price inflation of generic drugs and the high prices of innovative and recently launched branded drugs, the debate and rhetoric will eventually polarize. That polarization may be helped by new drugs with potentially very high list prices that are destined to be prescribed to very few patients.

You may also be interested in...



Teva Continues Divestitures To Close Allergan Deal With Sale To Impax

Impax will gain 15 approved generics and three pipeline assets, which will help address offset lower revenues of two of its existing top-sellers.

Stock Watch: Oncology Sands Shift At AstraZeneca And Merck

When AstraZeneca closed out big pharma earnings season, its usually dominant therapeutic franchise missed analysts’ expectations. Merck’s, on the other hand, did not disappoint.

Stock Watch: Novo Edges Ahead Of Lilly In GLP-1 Agonist Battle

The sales performances of the GLP-1 agonists dominated the earnings of Novo Nordisk and Lilly, with both stocks hitting 52-week highs after their results. But one moved ahead of the other in an important strategic bottleneck.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC065582

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel